about
Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.HACE1 is a putative tumor suppressor gene in B-cell lymphomagenesis and is down-regulated by both deletion and epigenetic alterations.The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma.Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis.The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age.Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy.Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.Rgb: a scriptable genome browser for R.Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study.The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma.Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.PET/CT before autologous stem cell transplantation predicts outcome in refractory/relapsed follicular lymphoma.Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma.Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma.Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study.Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemiaMediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
P50
Q36140942-7B32C524-3FD3-4BB5-BF7A-640E3876EC86Q38240579-E769FD03-54FD-41D0-9936-F4D9773FD75CQ38764010-46C7B17F-D804-48EC-BB8D-FE84E74B025DQ38776081-8D5AA49C-E5B6-43F5-8B8D-82E21584FA7DQ39280188-97595A4A-D15A-414E-B9D2-134AEDF38D63Q39951988-1BDAF95A-8D0E-41F9-AD61-E5264A4F65C5Q40353159-48CD5CAA-5AA3-44FD-B712-81E8828096E9Q42384499-4F329627-0C21-487D-B003-CAEDD3446703Q43004464-BE55E321-0673-4528-9C39-852D0A4EF72BQ43485442-E41D18C4-2165-43F7-9561-B49D1B47A766Q43778801-40278B2F-3735-445B-A5D6-1E13D6FF7497Q44093114-86AFC071-92C2-481C-BB91-98DF7601DC4AQ47605552-75CBD30C-1CA1-4A6F-9555-DFA915DA7EE2Q50953796-D09D2066-8494-4258-A5D2-47976A2C8D22Q51767473-A86B7B4F-6CFD-4CAD-93AE-28BAC58ABA2BQ52887085-97D1D9F0-F23E-44A2-98FE-E5C4A54C446FQ53083933-1D9DCE49-C68B-48E7-A9E3-5C9F8EF1E877Q53117498-EC35E2D3-DE9D-41D1-AC90-F9994B88FB1BQ53210229-C8BE1D92-80FA-430A-93DC-CB969D8775BDQ53537540-91A74A73-85FF-4408-B736-2414DF990C0AQ54392737-AC7AAB34-081F-4093-8420-91CE4FE8AAFBQ54753533-E13AE6AB-6BE6-4553-B4D0-AF7840C2E17DQ85521108-263D8BE2-1E34-4795-9B03-374F9D1944DFQ90524074-FF8888B8-228F-4734-8466-6EDE74FE4178
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sylvain Mareschal
@ast
Sylvain Mareschal
@en
Sylvain Mareschal
@es
Sylvain Mareschal
@nl
Sylvain Mareschal
@sl
type
label
Sylvain Mareschal
@ast
Sylvain Mareschal
@en
Sylvain Mareschal
@es
Sylvain Mareschal
@nl
Sylvain Mareschal
@sl
prefLabel
Sylvain Mareschal
@ast
Sylvain Mareschal
@en
Sylvain Mareschal
@es
Sylvain Mareschal
@nl
Sylvain Mareschal
@sl
P106
P21
P31
P496
0000-0001-7492-7528